New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
News|Articles|February 25, 2025
Medicaid Cuts Create Barriers for Oncologists and Patients With Cancer
Author(s)Jordyn Sava
Fact checked by: Gwen Nichols, MD
Gwen Nichols, MD, discussed the impact of Medicaid reductions on patient care and how oncologists can advocate for accessible cancer treatment during these uncertain times.
Advertisement
Advertisement
Medicaid reductions and delays in National Institutes of Health (NIH) research funding are posing significant challenges for cancer care, particularly affecting low-income patients and their providers.1,2
Related to this article
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.
Advertisement
Advertisement